Startup profile for Science Corporation: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Science Corporation funding, valuation and investors

CE-marked PRIMA retinal implant and wearable glasses for limited functional central-vision restoration, plus experimental biohybrid neural interfaces.

Verified company research · funding, investors and latest developments

Keep track of Science Corporation

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series D announced

$400M · November 17, 2026

Latest known valuation

$3.5B reported by TechCrunch citing unnamed source; pre/post-money basis unspecified

Series D announced · November 17, 2026

Total disclosed equity funding

$630M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · California, United States

Investors in latest funding

Other: Khosla Ventures , Ackman Oxman Institute , Tenet Healthcare , 885 Capital , Y Combinator , PLC Neurotech

Sources: latest funding · science.xyz Last verified: 2026-11-18T00:00:00.000Z

Overview

Founded in 2021 by Max Hodak, Science Corporation develops the PRIMA system: a subretinal photovoltaic microchip and specialized camera/projector glasses for selected patients with severe central-vision loss from geographic atrophy caused by dry age-related macular degeneration.

The glasses capture a scene and project encoded near-infrared light onto the implant, which stimulates remaining retinal neurons, enabling limited functional form vision in selected clinical-study patients. PRIMA received CE marking under EU medical-device rules in July 2026, permitting European commercialization; Science reported availability in Germany.

A practical patient journey is clinical eligibility and retinal evaluation, implantation at a specialist center, fitting of external camera/projector glasses, training and adjustment for magnification and task use, then long-term ophthalmology follow-up. This is an illustrative clinical workflow, not individual treatment advice or evidence of broad access.

The system does not restore normal natural colour vision or an unrestricted field of view. Its US Humanitarian Use Device and Breakthrough Device designations are NOT marketing authorizations; a Humanitarian Device Exemption approval is still needed. A separate programme combining cultured neurons and silicon interfaces is research-stage, not approved for human treatment.

Science announced $400M in Series D financing on November 17, 2026 with Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech among backers; no issuer-verified lead investor was named. TechCrunch reports a $3.5B valuation based on an unnamed person familiar with the deal, not a company filing.

Clinical-trial subgroup outcomes and PRIMA claims are not proof of commercial implant volume, established reimbursement levels or recurring revenue. Compare retinal implants with visual aids, accessibility support, and other experimental neural interface approaches by indication and regulatory status, not as equivalent therapies. Pricing, margins and US approval timing remain undisclosed.

Why Science Corporation is interesting

Science announced a $400M Series D after EU PRIMA commercialization authorization, while its reported $3.5B valuation and US regulatory prospects remain distinct from documented sales and clinical use.

Product & use cases

EU CE-marked PRIMA subretinal photovoltaic retinal prosthesis paired with camera-equipped glasses; separate biohybrid interface technology remains preclinical research. Series D is latest financing; stage directory enum cannot distinguish C/D.

  • Eligible EU patients with advanced geographic atrophy may receive specialist PRIMA implant evaluation and rehabilitation.
  • Specialist ophthalmology teams can evaluate functional vision, fit external glasses and monitor patient safety after implantation.
  • Preclinical research into cultured-neuron and electronics hybrid interfaces; not available as patient treatment.

Key facts

  • $400M Series D is new financing; >$900M historical lifetime capital reported by the company is not another round.
  • $3.5B valuation is journalist-reported, not issuer-confirmed, and its pre/post-money basis was not verified.
  • PRIMA has EU CE marking; US HUD designation is not FDA marketing approval.

Funding history (newest first)

Series D announced

2026-11-17T00:00:00.000Z $400M Valuation: $3.5B reported by TechCrunch citing unnamed source; pre/post-money basis unspecified
  • Khosla Ventures (participant)
  • Ackman Oxman Institute (participant)
  • Tenet Healthcare (participant)
  • 885 Capital (participant)
  • Y Combinator (participant)
  • PLC Neurotech (participant)

Source: Read source · science.xyz

Series C

2026-03-05T00:00:00.000Z $230M

Source: Read source · science.xyz

Competitive landscape

  • Low-vision magnification and adaptive aids alternative

    Nonimplant assistance for reading/tasks; does not provide direct retinal activation.

  • Neuralink Blindsight research adjacent

    Experimental visual-cortex interface, different mechanism and regulatory maturity.

  • Precision Neuroscience and Synchron adjacent

    Other implanted neural interfaces for different functional indications; not equivalent PRIMA retinal prostheses.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.